What is the real market size of the healthcare AI market?

The healthcare AI market is worth approximately 35 billion dollars in 2026, by our estimate. Published research puts it anywhere between 32 and 56 billion dollars, depending on what each firm counts.

Most research firms expect it to grow at 35 to 40 percent annually, making it one of the fastest-expanding enterprise software categories.

Adoption is now mainstream: 81 percent of US physicians used AI at work in early 2026, up from 38 percent in 2023.

And if you want to better understand this new industry, you can download our pitch covering the healthcare AI.

How do we define the healthcare AI?

We define the healthcare AI market as AI software and models used by healthcare providers, payers, life sciences companies, medtech firms, and public health bodies to improve clinical care, operations, and research.

We include clinical decision support, diagnostic and monitoring tools, hospital and clinic workflow and revenue cycle automation, payer analytics and claims tools, as well as AI used in pharma and biotech R&D, clinical trials, and connected medical devices.

We exclude general-purpose AI infrastructure, pure consumer wellness and fitness apps, and horizontal enterprise tools that are not purpose-built or primarily sold for healthcare use.

We also use this definition when we make and update our pitch covering everything there is to know about the healthcare AI

What is the size of the healthcare AI in 2026?

What results can we find on the internet?

As you probably know already, many firms regularly publish (sometimes conflicting) estimates of the healthcare AI size, using different definitions, scopes, and years.

We have consolidated their latest results here. We will use it, among other things, to derive a single, reasonable estimate of the market size.

Research Firm	Market Size	Year	Market Definition
Fortune Business Insights	$56.01B	2026	Software, services and applications including robotic surgery and virtual nursing. Broader than our definition as robotic surgery brings hardware revenue. Published October 2026.
Precedence Research	$51.20B	2026	Clinical, operational and device-related AI. Its hardware and device categories make it broader than our scope.
Polaris Market Research	$51.09B	2026	Wide healthcare AI classification including hardware-linked applications. Broader than our definition.
Grand View Research	$50.70B	2026	Hardware, software and services, extending into robotic surgery, clinical trials and cybersecurity. Only part of it matches our definition.
SkyQuest Technology	$37.70B	2025	Hardware, services, robotic surgery and virtual assistants. Broader than our scope and based on an older (December 2025) publication.
MarketsandMarkets	$36.67B	2026	Imaging, AI scribes, clinical decision support, revenue cycle, telehealth, robotics and cybersecurity. The closest match to our categories, though robotics and cybersecurity go beyond our scope.
The Business Research Company	$31.97B	2026	Hardware, software, services, surgical robotics, virtual assistants and pharma applications, including AI imaging devices and wearables.
IMARC Group	$9.8B	2025	Hardware, software, services, robot-assisted surgery and patient-facing uses. Despite the broad scope, it gives a much smaller base than other firms.

What can we conclude, then?

The six firms that publish a 2026 figure range from 31.97 billion dollars to 56.01 billion dollars, with a median around 51 billion dollars. The IMARC and SkyQuest figures are for 2025, so they are not the low end of the 2026 range.

The gap between high and low estimates mostly reflects whether firms count hardware, robotic surgery, wearables and cybersecurity. Most of the 50 billion dollar figures include them.

Given our definition, which covers AI software and models but not robotics hardware, we estimate the healthcare AI market at approximately 35 billion dollars in 2026. That sits near MarketsandMarkets (36.67 billion dollars), whose categories match ours best, and this is our first estimate that we will refine further.

What if we try to make our own estimate?

We don't have to rely only on external analyses to estimate market size.

We will try to build a first-principles, bottom-up calculation, then run a few sanity checks to see whether we can reliably estimate the size of the healthcare AI.

Useful data about the healthcare AI

Here is some useful and reliable data we have collected, they will help us estimate the size of the healthcare AI:

• The US has 6,120 hospitals including 5,129 community hospitals with 784,112 staffed beds as of 2022 (AHA Annual Survey 2024)
• US healthcare IT spending is about 63 billion dollars a year, of which medical documentation (19.6 billion) and revenue cycle back office (18.8 billion) make up about 60 percent (Menlo Ventures)
• Healthcare AI as share of IT spending grew from 5.5 percent in 2022 to 10.5 percent plus in 2024, doubling in two years (HealthIT.gov)
• US spending on domain-specific healthcare AI tools reached 1.4 billion dollars in 2025, nearly three times 2024, including 600 million for ambient documentation and 450 million for coding and billing (Menlo Ventures)
• 71 percent of US hospitals use predictive AI integrated with their EHR in 2024, up from 66 percent in 2023 (HealthIT.gov)
• 81 percent of US physicians used AI professionally in early 2026, up from 38 percent in 2023 (American Medical Association)
• The US represents about 40 percent of the global healthcare AI market in 2026 (22.70 billion of 56.01 billion dollars in a broad scope) (Fortune Business Insights)
• The AI in revenue cycle management market is estimated at 21.49 billion dollars in 2026, in a broad scope that overlaps with existing RCM software and services (Mordor Intelligence)
• The AI in drug discovery market is estimated at 2.9 billion dollars in 2026 (Grand View Research)
• The FDA had authorized more than 1,600 AI-enabled medical devices as of September 2026 (FDA)
• Some company figures give a sense of scale: OpenEvidence at about 300 million dollars of annualized revenue in July 2026 and Commure at about 200 million, both third-party estimates, and Tempus AI at 93.2 million dollars of Data and Applications revenue in Q2 2026 (Sacra, Tempus AI)

Method and calculation to get the size of the healthcare AI

Let's start with US healthcare IT budgets as the foundation. US healthcare organizations spend about 63 billion dollars a year on IT.

Healthcare AI represented 10.5 percent of IT spending in 2024, up from 5.5 percent in 2022. Applying 10.5 percent to 63 billion dollars yields approximately 6.6 billion dollars of AI spending inside US healthcare IT budgets.

That is much more than Menlo's 1.4 billion dollars, and it should be. Menlo only counts new, domain-specific AI tools, while a lot of AI is sold as a feature inside larger platforms such as Epic, Waystar or imaging systems, and is never reported separately.

The US represents about 40 percent of the global market. Scaling up our 6.6 billion dollars gives roughly 16 billion dollars of AI bought through healthcare IT budgets worldwide.

But IT budgets are just one part. Pharma and biotech pay for AI from R&D budgets: drug discovery AI alone adds about 2.9 billion dollars.

A large share of AI revenue cycle work is also sold as outsourced services rather than software. Mordor puts the whole AI RCM market at 21.49 billion dollars, but much of it overlaps with what we already counted.

If we count only the part of AI RCM services not already inside IT budgets, roughly half to all of it, we reach 30 to 40 billion dollars.

After adjusting for overlaps and ensuring we capture all segments, our bottom-up estimate points to approximately 35 billion dollars for 2026.

Sanity checks

Our estimate of about 35 billion dollars sits at the low end of the published 2026 range of 32 to 56 billion dollars, which makes sense since the highest estimates include hardware and robotic surgery.

The global healthcare IT market is 313 to 760 billion dollars depending on scope. Our healthcare AI estimate of 35 billion dollars represents about 5 to 11 percent of healthcare IT spending.

This percentage matches the observed 10.5 percent AI penetration rate in hospital IT budgets. It also leaves plenty of room: documentation and RCM alone take 38.4 billion dollars of US IT budgets that AI can replace or improve.

With 71 percent of US hospitals using predictive AI and 81 percent of physicians using AI at work, we should see significant spending. But only 52 percent of health system leaders say they are ready to deploy AI at scale, and 48 percent cite budget limits (Guidehouse and HIMSS, February 2026).

The more than 1,600 FDA-authorized AI devices also indicate a substantial market, although many of these products generate little revenue and many include hardware.

Investment stays strong: US digital health raised 7.4 billion dollars across 244 deals in H1 2026, with 115 acquisitions (Rock Health). These are broad digital health figures, not AI-only.

Large private valuations add to the picture: OpenEvidence at a reported 15 billion dollars, Chai Discovery at 3.8 billion and Hippocratic AI at 3.5 billion.

What's our final guess then?

Based on our analysis of published estimates, bottom-up calculations, and validation checks, we estimate the healthcare AI market at approximately 35 billion dollars in 2026.

The same research firms put the market at 26 to 29 billion dollars in 2024. Their 2026 figures climbed to 51 billion dollars or more, but a large part of that comes from hardware and robotics we do not count.

The healthcare AI market in 2026 is slightly larger than the global cybersecurity software market at approximately 30 billion dollars. It is also similar to the customer relationship management software market at around 32 billion dollars.

These comparisons make intuitive sense. Healthcare AI is transforming a 4 trillion dollar US healthcare system and an 8 trillion dollar global healthcare economy.

The market size reflects early-stage penetration with massive room for growth.

The 35 billion dollar healthcare AI market in 2026 also aligns with infrastructure metrics. With 150,000 plus hospitals globally and 81 percent of US physicians using AI, the spending levels support this market size.

Is the healthcare AI market mature, competitive or fragmented?

The maturity score of the healthcare AI in 2026 is 35/100

The healthcare AI market in 2026 shows early-stage characteristics despite rapid growth. Only 22 percent of US healthcare organizations had deployed domain-specific AI tools in 2025 (27 percent of health systems), and only 52 percent of health system leaders feel ready to deploy AI at scale.

Rules are still being written. The FDA finalized its Predetermined Change Control Plans guidance only in December 2024, the EU AI Act's high-risk obligations apply from December 2027, and US payment for clinical AI remains patchy: CMS is testing outcomes-based payments with its ACCESS model, not paying for AI software across the board.

These indicators point to a market still in its formative years.

However, certain segments show higher maturity. Ambient clinical documentation is the largest measured category, with 600 million dollars of US spending in 2025, though only about 35 percent of clinicians at large health systems use it.

Medical imaging also runs at production scale: Aidoc analyzes more than 60 million patient cases a year, and Viz.ai is used in nearly 2,000 US hospitals.

The competitive score of the healthcare AI in 2026 is 75/100

The healthcare AI market in 2026 is highly competitive, with large specialist startups, EHR incumbents and now general AI platforms fighting for the same budgets.

Competition is intense in ambient clinical documentation where Microsoft's Nuance with 33 percent market share faces strong challenges from Abridge at 30 percent and Ambience at 13 percent. With Suki at about 10 percent, four vendors hold roughly 86 percent, yet 67 percent of outpatient buyers say they are willing to switch.

Microsoft's Dragon Copilot alone had more than 100,000 clinician users by March 2026.

Platform players like Epic, Oracle Health, and athenahealth are building AI directly into EHR systems. More than 85 percent of Epic customers used Epic AI by March 2026.

General AI companies add pressure: OpenAI made ChatGPT free for verified US clinicians in April 2026 and connected it to Epic records in September, while Anthropic and Google keep expanding their healthcare and life sciences offers.

The fragmentation score of the healthcare AI in 2026 is 85/100

The healthcare AI market in 2026 is highly fragmented, with more than 1,600 FDA-authorized AI-enabled devices (from fewer companies, since one company can hold several). Multiple distinct subcategories each have different leaders with no dominant player across segments.

The market structure reflects specialization by clinical area, use case, and customer segment. Imaging and pathology, revenue cycle management, clinical decision support, patient engagement, life sciences, and ambient documentation each have separate competitive dynamics.

Only ambient documentation has a measured concentration. Across the whole market, no reliable top-five ranking exists.

Consolidation is under way: Roche agreed to buy PathAI and Tempus agreed to buy Personalis for about 1.5 billion dollars, both announced in 2026, and Rock Health counted 115 digital health acquisitions in H1 2026. Private equity firms are executing roll-up strategies combining AI-native startups with legacy players.

Despite this activity, the healthcare AI market in 2026 remains one of the most fragmented enterprise software categories.

How much bigger will the healthcare AI be in 10 years?

What are the different forecasts for the growth rate of healthcare AI?

One more time, let's check what other market research firms have to say.

Research Firm	Annual Growth Rate	Until Year	Comments
Fortune Business Insights	43.96%	2034	Broad scope including robotic surgery inflates growth rate. Forecasts 1,033 billion dollars by 2034. We should weight this lower.
MarketsandMarkets	39.7%	2031	Categories closest to ours. Forecasts 194.79 billion dollars by 2031. Reliable for our estimate.
Grand View Research	38.9%	2033	Includes hardware, robotic surgery and cybersecurity. Forecasts 505.59 billion dollars by 2033. Growth rate in line with the consensus.
Polaris Market Research	38.7%	2034	Wide classification including hardware-linked uses. Forecasts 702.10 billion dollars by 2034.
SkyQuest Technology	37.3%	2033	Broad scope and an older publication. Forecasts 476.14 billion dollars by 2033. Reliable mid-range estimate.
Precedence Research	35.02%	2035	Includes device-related AI. Longest forecast, to 744.34 billion dollars by 2035. Useful for long-term projections.
The Business Research Company	30.2%	2030	Includes hardware and robotics, yet gives the lowest 2026 base. Forecasts 91.85 billion dollars by 2030.
IMARC Group	24.0%	2034	Outlier low estimate from a much smaller base. Forecasts 71.60 billion dollars by 2034. Should be weighted lower.

What can we conclude about the growth rate of the healthcare AI?

Five of eight research firms cluster in the 35 to 40 percent CAGR range, providing strong consensus for the healthcare AI growth rate. The median across all sources is approximately 38 percent annually.

The outlier low estimate at 24 percent from IMARC starts from a much smaller base. The outlier high at 43.96 percent from Fortune Business Insights includes robotic surgery.

We can exclude these extremes from our central estimate.

Keep in mind that these growth rates measure expectations, not verified demand. Identifiable AI software purchases still start from a small base, like Menlo's 1.4 billion dollars for the US in 2025.

Given our comprehensive definition that includes clinical AI, administrative automation, and life sciences R&D, a growth rate of 37 percent CAGR through 2030 is appropriate. This aligns with the consensus cluster.

After 2030, growth rates typically moderate as markets mature, so we estimate 30 to 32 percent CAGR from 2030 to 2036.

With a 37 percent CAGR from our 2026 base of 35 billion dollars, the healthcare AI market would reach approximately 123 billion dollars by 2030. This represents a 3.5 times multiple over four years.

This projection sits between The Business Research Company's 92 billion dollars for 2030 and MarketsandMarkets' 195 billion dollars for 2031.

Extending to 2036 with 37 percent CAGR through 2030 and then 31 percent CAGR from 2030 to 2036, the healthcare AI market would reach approximately 620 billion dollars. This represents an 18 times multiple over ten years.

This ten-year projection fits within the 500 to 750 billion dollar range that most research firms project for 2033 to 2035, while Fortune Business Insights goes above 1 trillion dollars.

For comparison, the cloud computing market grew at approximately 25 percent CAGR and the cybersecurity market at 12 percent CAGR over similar periods. The healthcare AI growth rate of 37 percent exceeds both.

This reflects how fast healthcare has moved: AI use among US physicians more than doubled between 2023 and 2026.

What is the projected CAGR for the healthcare AI?

At New Market Pitch, we like it when the information is clear and easy to digest, as you will see in the pitch about the healthcare AI. That's also why we have made this clear summary table.

Year	Worst Case (28% annual growth rate)	Realistic (37% annual growth rate)	Best Case (45% annual growth rate)
2027	$44.8B	$48.0B	$50.8B
2028	$57.3B	$65.7B	$73.6B
2029	$73.4B	$90.0B	$106.7B
2030	$94.0B	$123.3B	$154.7B
2031	$120.3B	$168.9B	$224.3B
2032	$153.9B	$231.4B	$325.3B
2033	$197.0B	$317.0B	$471.7B
2034	$252.2B	$434.3B	$683.9B
2035	$322.8B	$595.0B	$991.7B
2036	$413.2B	$815.2B	$1,438.0B

What would it take for the healthcare AI to be worth $700 billion?

Reaching $700 billion by 2036 would require adoption to go deeper than current projections. Today, 71% of US hospitals use predictive AI and 81% of physicians use AI at work, but only 22% of organizations have deployed domain-specific tools: this would need to reach 95%+ across hospitals, physician practices, payers, and life sciences companies.

Clinical decision support AI must overcome significant barriers. The AI-specific CDS market is only about 1.5 billion dollars in 2026. The Peterson Health Technology Institute notes that today's payment model favors administrative automation over clinical AI, so reimbursement, evidence requirements, and liability frameworks would all need faster resolution.

Pharma and biotech AI requires breakthrough validation. Drug discovery AI is about 2.9 billion dollars in 2026 and expected to reach 13.8 billion by 2033. Deals like AstraZeneca and insitro (40 million dollars upfront, up to 1.46 billion in milestones that may never be paid) show appetite, but multiple AI-discovered drugs reaching market would be needed to go much faster.

International expansion must exceed current trajectories. Asia-Pacific is expected to grow about 45% in 2026 alone, but China, Japan and India would need major healthcare AI infrastructure investments.

Payer AI adoption must match provider levels. Documentation and coding already take 75% of measured US AI spending, but full integration across claims processing, prior authorization, fraud detection, and medical necessity determinations would unlock major spending.

Ambient clinical documentation must move beyond note-taking to integration depth: shifting from pilots to full deployment across all clinical encounters, and from transcription to coding and other downstream tasks, at a time when prices are under pressure.

Revenue cycle management AI (about $21.5 billion in 2026) would need to exceed its projected 27.1% CAGR, reaching $250 billion+ by 2036 instead of about $240 billion. This requires near-complete automation of claims, coding, billing, and collections.

Where is the money in the healthcare AI?

What are the categories and how much do they generate?

Revenue cycle management AI dominates the healthcare AI market in 2026 with approximately 21.5 billion dollars, representing about 60 percent of total spending. This includes claims processing, coding, billing, and collections automation, and overlaps with established RCM software and services.

The concentration reflects healthcare organizations prioritizing ROI-positive administrative applications over higher-risk clinical AI.

Ambient clinical documentation generates approximately 2.5 billion dollars globally in 2026 (Meticulous Research), with 600 million dollars of US spending in 2025, the largest category in Menlo's study. Microsoft's Nuance, Abridge, and Ambience lead this segment.

Abridge alone works with more than 300 health systems covering over 250 million patients.

Medical imaging and diagnostics AI generates approximately 2.5 billion dollars in 2026, about 7 percent of the healthcare AI market. Broader studies that include AI-enabled devices reach 20 billion dollars for radiology alone.

However, reimbursement challenges limit revenue despite clinical validation.

Drug discovery and pharma R&D AI produces approximately 2.9 billion dollars in 2026, roughly 8 percent of the healthcare AI market. Pharma and biotech companies are the main buyers.

Large rounds like Chai Discovery's 400 million dollars support continued expansion.

Clinical decision support (about 1.5 billion dollars), clinical trials AI, patient engagement, and remote monitoring collectively generate the remaining 5 to 6 billion dollars, about 15 percent. These categories have lower maturity rates.

Note that these category figures come from different studies with different scopes. Added together, the six headline category estimates reach 42 billion dollars, more than some estimates for the whole market, so treat the split as indicative.

Finally, if you really want to understand where is the money, you can check our ranking of the most funded startups in the healthcare AI market as well as our list of the most valued startups.

How will it evolve?

By 2030, revenue cycle management AI will decline to about 45 percent of the healthcare AI market as clinical AI matures. RCM will grow to about 55 billion dollars at Mordor's 27.1 percent annual growth, but represents a smaller share.

Administrative AI approaching saturation allows clinical applications to capture incremental spending.

Ambient clinical documentation will grow to about 5.5 billion dollars by 2030 and 17.6 billion by 2036 (21.8 percent a year, Meticulous Research). It stays a small share of the market as prices fall and EHR vendors bundle it.

Integration depth rather than adoption breadth becomes the revenue driver.

Medical imaging and diagnostics AI will grow at about 35 percent a year to roughly 8 billion dollars by 2030 and 20 billion by 2033. Wider reimbursement and FDA's streamlined PCCP guidance would accelerate clinical AI adoption.

Pathology is gaining weight beyond radiology, as Roche's PathAI deal shows.

Drug discovery AI will reach about 7 billion dollars by 2030 and 13.8 billion by 2033 (24.8 percent a year), with clinical trials AI adding more. Pharma deals such as AstraZeneca with insitro and with Oracle on trial recruitment point to growing budgets.

These category forecasts grow slower than the 37 percent we use for the whole market, so a large part of the growth has to come from newer uses: prior authorization, care coordination, patient follow-up, and life sciences workflows.

By 2036, the revenue distribution shifts further toward clinical applications. RCM stabilizes at 35 to 40 percent while clinical decision support, diagnostics, and pharma R&D collectively reach 40 to 45 percent of a roughly 600 to 700 billion dollar healthcare AI market.

Ambient documentation becomes mature infrastructure supporting clinical workflows.

Where to spend your energy as an investor or a builder in the healthcare AI then?

For investors seeking near-term returns, workflows with a direct financial payoff offer the clearest opportunity: prior authorization, denials, and complex revenue cycle tasks. Buyers expect a return of 3 to 3.9 times their investment, and these workflows can prove it.

Generic ambient scribes are now crowded, with three vendors holding 76 percent. The opportunity is in specialty documentation that flows into coding and other downstream tasks.

Revenue cycle management AI provides defensive positioning with about 21.5 billion dollars current market size and established reimbursement models. However, the segment's projected market share decline to about 45 percent by 2030 suggests limited expansion multiples.

Private equity roll-up strategies combining AI-native startups with legacy RCM players represent the main value creation path.

Drug discovery and clinical trials AI offer high long-term upside, with clinical-trial matching among the most attractive segments. Chai Discovery raising 400 million dollars at a 3.8 billion valuation, after Xaira Therapeutics raised 1 billion dollars at launch, demonstrates investor appetite.

However, longer time horizons of 5 to 10 years for AI-first drug approvals require patient capital.

Clinical decision support AI remains nascent at about 1.5 billion dollars but represents massive untapped potential. Generic clinical chatbots, though, now face OpenAI's free ChatGPT for clinicians and OpenEvidence, which reached about 300 million dollars of annualized revenue.

Builders focusing on specific clinical workflows with clear ROI metrics, or on AI quality assurance and governance, can capture first-mover advantages. Utah's healthcare AI sandbox, with six independent evaluators named in October 2026, shows that demand for testing is growing.

Geographic expansion into Asia-Pacific, the region with the highest projected long-term growth, offers growth arbitrage. China, Japan and India are expanding healthcare infrastructure and AI adoption.

However, regulatory complexity and localization requirements demand operational expertise beyond North American market experience.

And if you're curious about where investors are putting their money right now, we publish a quarterly update on the fundraising activity in the healthcare AI here. We also analyze long-term funding trends in the healthcare AI here.

What is the geographical revenue breakdown for the healthcare AI?

North America

North America holds about 44 percent of the healthcare AI market in 2026, or approximately 15 to 16 billion dollars on our estimate (Fortune Business Insights puts it at 24.78 billion dollars with a broader scope). The United States accounts for about 92 percent of the region, with advanced healthcare infrastructure and most of the 1,600 plus FDA AI device authorizations.

US digital health funding reached 7.4 billion dollars in H1 2026 across 244 deals.

By 2030, North America's market share will decline slightly to 42 to 48 percent as Asia-Pacific accelerates. However, absolute revenue will grow to 52 to 59 billion dollars driven by universal provider adoption.

71 percent of hospitals already using predictive AI will reach 95 percent plus penetration.

By 2036, North America stabilizes at 38 to 42 percent of the global healthcare AI market, generating 235 to 260 billion dollars. Market share decline reflects faster international growth rather than domestic weakness.

The US maintains technology leadership through continued innovation from well-funded specialists like Abridge, OpenEvidence and Hippocratic AI, and from the big AI platforms.

Canada represents 8 to 12 percent of North American healthcare AI spending with government healthcare systems driving adoption. Provincial health authorities implementing AI across standardized infrastructure accelerates deployment.

Europe

Europe captures about 28 percent of the healthcare AI market in 2026, generating approximately 10 billion dollars on our estimate. The United Kingdom leads European adoption with NHS active deployment programs.

Germany shows strength in pharma AI given concentration of pharmaceutical and biotech companies.

By 2030, Europe maintains 24 to 27 percent market share reaching 30 to 33 billion dollars. The EU AI Act adds compliance work: its general obligations started applying in August 2026, and high-risk rules come in from December 2027 and August 2028.

Stricter data privacy frameworks such as GDPR attract healthcare organizations concerned about patient data security.

By 2036, Europe holds 22 to 25 percent of the healthcare AI market generating 135 to 155 billion dollars. The region benefits from universal healthcare systems enabling standardized AI deployment.

However, fragmented procurement across countries limits economies of scale compared to US market concentration.

France, Germany, UK, and Nordic countries collectively represent 70 to 75 percent of European healthcare AI spending. Eastern European markets remain underdeveloped due to lower healthcare IT infrastructure investment.

Asia-Pacific

Asia-Pacific holds about 21 percent of the healthcare AI market in 2026, generating approximately 7.5 billion dollars on our estimate. The region is the fastest growing, up about 45 percent in 2026 alone according to Fortune Business Insights.

China, Japan and India drive the growth as healthcare infrastructure and AI adoption expand.

By 2030, Asia-Pacific will reach 26 to 30 percent of global healthcare AI market producing 32 to 37 billion dollars. China's Baidu Health partnerships and 60 percent plus share of global population create massive addressable market.

India and Southeast Asia contribute growing share as healthcare infrastructure modernizes.

By 2036, Asia-Pacific captures 32 to 38 percent of the healthcare AI market generating 200 to 235 billion dollars. The region will rival or exceed North America in absolute spending.

Demographic advantages including aging populations in Japan and China plus middle class expansion in India drive healthcare AI investment.

Japan maintains highest hospital density in OECD at 8,156 hospitals creating strong institutional demand. Australia and New Zealand represent high-value markets with advanced healthcare systems similar to North America.

Latin America

Latin America represents about 4 percent of the healthcare AI market in 2026, generating approximately 1.4 billion dollars on our estimate. Brazil and Mexico are key markets with large populations and growing healthcare systems.

However, lower healthcare IT spending per capita limits market size.

By 2030, Latin America grows to 4 to 5 percent market share reaching 5 to 6 billion dollars. Government initiatives to modernize healthcare infrastructure drive AI adoption.

Telemedicine expansion during COVID accelerated digital health readiness creating foundation for AI deployment.

By 2036, Latin America reaches 5 to 6 percent of the healthcare AI market producing 30 to 37 billion dollars. Economic development and healthcare system maturation support steady growth.

However, the region continues lagging North America and Asia-Pacific in per capita AI spending.

Middle East and Africa

Middle East and Africa holds about 2 percent of the healthcare AI market in 2026, generating approximately 0.8 billion dollars on our estimate. Gulf Cooperation Council countries lead with significant government investment in healthcare infrastructure.

Sub-Saharan Africa remains underdeveloped but mobile health adoption creates leapfrog opportunities.

By 2030, Middle East and Africa grows to 2.5 to 3 percent market share reaching 3 to 4 billion dollars. UAE and Saudi Arabia Vision 2030 initiatives include substantial healthcare AI components: in October 2026, AstraZeneca, Oracle and Abu Dhabi's M42 announced a collaboration on AI for hypertension care and trial recruitment, though no contract value was disclosed.

South Africa represents largest sub-Saharan market with established private healthcare sector.

By 2036, Middle East and Africa reaches 3 to 4 percent of the healthcare AI market generating 19 to 25 billion dollars. Oil-producing nations diversifying economies prioritize healthcare technology investments.

However, political instability and limited healthcare infrastructure in many African nations constrain broader regional growth.